TY - JOUR
T1 - An Infectious Diseases Perspective on Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children
AU - Cotter, Jillian M.
AU - Nicholson, Maribeth R.
AU - Kociolek, Larry K.
N1 - Funding Information:
Synthetic Biologics, has received research supplies from Alere, and has received research grants from Merck and Cubist. The remaining authors: No reported conflicts. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Publisher Copyright:
© 2019 The Author(s). Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Fecal microbiota transplantation (FMT) is efficacious for treatment of recurrent Clostridioides difficile infections (rCDIs). Pediatric experience with FMT for rCDIs is increasing, particularly at large centers. While retrospective studies suggest that FMT is generally safe in the short term, particularly in immunocompetent patients and with rigorous donor screening, additional large prospective studies are needed. This particularly includes those at high risk for infectious complications, such as immunocompromised hosts. Further, long-term implications of altering the intestinal microbiome with FMT are not well understood. The role of FMT in children, particularly in high-risk patients, will require continual reexamination with future availability of pediatric safety and efficacy data. This review summarizes key points for infectious diseases physicians to consider when evaluating a child for FMT.
AB - Fecal microbiota transplantation (FMT) is efficacious for treatment of recurrent Clostridioides difficile infections (rCDIs). Pediatric experience with FMT for rCDIs is increasing, particularly at large centers. While retrospective studies suggest that FMT is generally safe in the short term, particularly in immunocompetent patients and with rigorous donor screening, additional large prospective studies are needed. This particularly includes those at high risk for infectious complications, such as immunocompromised hosts. Further, long-term implications of altering the intestinal microbiome with FMT are not well understood. The role of FMT in children, particularly in high-risk patients, will require continual reexamination with future availability of pediatric safety and efficacy data. This review summarizes key points for infectious diseases physicians to consider when evaluating a child for FMT.
KW - Clostridioides difficile
KW - Clostridium difficile
KW - fecal microbiota transplantation
KW - safety
KW - screening
UR - http://www.scopus.com/inward/record.url?scp=85075647601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075647601&partnerID=8YFLogxK
U2 - 10.1093/jpids/piz062
DO - 10.1093/jpids/piz062
M3 - Article
C2 - 31550348
AN - SCOPUS:85075647601
SN - 2048-7207
VL - 8
SP - 580
EP - 584
JO - Journal of the Pediatric Infectious Diseases Society
JF - Journal of the Pediatric Infectious Diseases Society
IS - 6
ER -
